Yantai Dongcheng Pharmaceutical Group (002675) Fair Value & Analysis

Healthcare · CN · Market cap 10.2B CNY

A solid business, but screening 61% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (¥6.52). The favourable scenario is already priced in.
• Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
• A fairly wide model range (¥3.34 to ¥6.52) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.

How to read this chart

60‑month range ¥9.67 – ¥21.71 · fair‑value band ¥3.34 – ¥6.52 · the ¥13.16 price screens above the ¥5.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Yantai Dongcheng Pharmaceutical Group (002675) currently trades at ¥13.16, while our model-based Fair Value estimate is ¥5.16, implying the stock looks roughly 60.8% overvalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Yantai Dongcheng Pharmaceutical Group generated revenue of 2.7B CNY at a net margin of 7.6%. Revenue declined 8.8% year over year. It earns a return on equity of 3.2%. Net debt stands at 1.7B CNY. Fundamentals as of Jul 22, 2026

Our scenario range runs from ¥3.34 (bear case) to ¥6.52 (bull case); at ¥13.16, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -61%, 002675 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (¥6.22) versus Dividend Discount (¥0.4800). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. engages in the raw materials, formulations, nuclear medicine, and big health businesses in China and internationally. It operates through API, Formulation, Radio Pharmaceutical, and Others segments.

Full company description

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. engages in the raw materials, formulations, nuclear medicine, and big health businesses in China and internationally. It operates through API, Formulation, Radio Pharmaceutical, and Others segments. The company offers formulation products, such as powder injections, tablets, capsules, granules, and drop pills for anticoagulation, cardiovascular, anti-tumor, urology, orthopedics, and anti-infection applications. It also provides active pharmaceutical ingredients, including heparin, chondroitin sulfate sodium and calcium, hyaluronic acid, cytochrome C, and collagen, as well as glucosamine hydrochloride, glucosamine sulfate sodium chloride, and glucosamine sulfate potassium chloride; and nadroparin calcium for injection, hydrocortisone sodium succinate for injection, chorionic gonadotrophin for injection, menotropins for injection, ambroxol hydrochloride dispersible tablets, jinjunling capsules, metformin hydrochloride and glibenclamide tablets, clemastine fumarate tablets, and wind-dispelling itch-relieving granules. In addition, the company offers Technetium Methylene Diphosphonate injections; Technetium Tc=labeled tracers; 2-[18F]FDG for early diagnosis of tumors; sodium iodide oral solution; iodine seeds used for internal radiation treatment of various malignant tumors; urea capsules; and jiabaolin glucosamine chondroitin sulfate capsules. Further, it engages in trading; medical technology; medical devices; technical services; biotechnology service promotion; medical research and experimental development; business services; enterprise management, business information, and financial consulting; multimodal transport and transport agency services; capital market services; operation of local platforms for images; and engineering activities. The company exports its products to approximately 40 countries and regions. Yantai Dongcheng Pharmaceutical Group Co.,Ltd. was founded in 1998 and is headquartered in Yantai, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Yantai Dongcheng Pharmaceutical Group reported revenue of ¥2.7B in FY2025 versus ¥3.9B in FY2021, a compound −8.7%/yr. Reported net income was ¥196M in FY2025, compounding +6.6%/yr from FY2021.

002675 screens 61% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 626 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.